Headache News and Research

Latest Headache News and Research

Biogen Idec launches educational forum, 'Women in MS'

Biogen Idec today announced the launch of "Women in MS," an educational initiative to address both the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis.

25 May 2011

Viewpoints: Pawlenty weighs in; entitlement reform dominating GOP politics

"ObamaCare" is unconstitutional, and it is already driving up health costs — not reducing them. ... Government money isn't "free." ... And the cuts we must make cannot just be in other people's favorite programs. ... This week I'm going to Florida to tell both young people and seniors that our entitlement programs are on an unsustainable path and have to be changed.

25 May 2011

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

The U.S. Food and Drug Administration today approved Incivek treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa and ribavirin.

24 May 2011

Substantial portion of patients with headaches improve without treatment

Headache is a very common complaint, with over 90% of all persons experiencing a headache at some time in their lives. Headaches commonly are tension-type (TTH) or migraine. They have high socioeconomic impact and can disturb most daily activities. Treatments range from pharmacologic to behavioral interventions.

23 May 2011

Huntsman's stance on Utah health mandate questioned

During a campaign stop Friday, former Gov. Jon Huntsman Jr. presented Utah's health reform as a model for what other states could do. And, Huntsman pointed out, Utah did not mandate that people buy health insurance, unlike the Massachusetts model now a thorn for Mitt Romney. His assertion, however, was called into question by a story in the Huffington Post, under the headline "Huntsman vs. Huntsman," which quoted Utah health policy players who said Huntsman had wanted a mandate but didn't get it.

23 May 2011

Edurant receives FDA approval for treatment of HIV-1 infection

The U.S. Food and Drug Administration today approved Edurant (rilpivirine) in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naive).

21 May 2011

EMA CHMP recommends conditional marketing authorization of FAMPYRA

The Committee for Medicinal Products for Human Use of the European Medicine Agency has recommended conditional marketing authorization of FAMPYRA (prolonged-release fampridine 10 mg tablets) for the improvement of walking in adult patients with multiple sclerosis with walking disability.

20 May 2011

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

20 May 2011

Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced results from the ASPIRE phase 2b study that evaluates the addition of once daily TMC435 to pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon (PegIFN) and ribavirin (RBV) was unsuccessful either because they relapsed, had a partial response or had a null response.

20 May 2011

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

The U.S. Food and Drug Administration today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of the ACCORD Lipid study as they relate to the use of fenofibric acid (sold as Trilipix in the United States) in combination with a statin in patients with mixed dyslipidemia and at high risk of heart disease.

20 May 2011

Complementary and alternative health practices show promise for management of pain

A variety of complementary and alternative health practices —including meditation and relaxation techniques, manual therapies such as massage and spinal manipulation, meditative exercise forms such as yoga, Tai Chi, and ancient health practices such as acupuncture—show promise for contributing to the management of pain according to research presented at the Annual Scientific Meeting of the American Pain Society, www.ampainsoc.org.

20 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Micromet, Inc. today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive acute lymphoblastic leukemia were published in the May 16th on-line edition of the Journal of Clinical Oncology.

18 May 2011

Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints

VIVUS, Inc. today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C.

18 May 2011

Eli Lilly responds to Amylin's exenatide lawsuit

Eli Lilly and Company has provided additional perspective in response to Amylin Pharmaceuticals, Inc.'s lawsuit filed in the United States District Court for the Southern District of California.

17 May 2011

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

AstraZeneca today announced results from a long-term study comparing SYMBICORT Inhalation Aerosol 160/4.5 mcg with budesonide pressurized metered-dose inhaler 160 mcg in self-reported African American patients with moderate to severe persistent asthma.

17 May 2011

FDA nod for hepatitis C drug

Merck & Co have finally won the Food and Drugs Administration – FDA’S approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus. The drug brand named, Victrelis is expected to help transform treatment of the potentially fatal disease with higher cure rates and shorter courses of therapy for some patients. Merck shares rose 0.6 percent in after-hours trading to $37.33, up from their $37.08 close on the New York Stock Exchange. Approval of Victrelis was widely expected after a FDA advisory panel recommended the drug in an 18-0 vote in April.

17 May 2011

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Amylin Pharmaceuticals, Inc. today announced that it has filed a lawsuit against Eli Lilly and Company in the United States District Court for the Southern District of California, alleging that Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide.

16 May 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

The U.S. Food and Drug Administration today approved Victrelis (boceprevir) to treat certain adults with chronic hepatitis C. Victrelis is used for patients who still have some liver function, and who either have not been previously treated with drug therapy for their hepatitis C or who have failed such treatment.

16 May 2011

Headache News and Research

Latest Headache News and Research

Biogen Idec launches educational forum, 'Women in MS'

Viewpoints: Pawlenty weighs in; entitlement reform dominating GOP politics

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

Substantial portion of patients with headaches improve without treatment

Huntsman's stance on Utah health mandate questioned

Edurant receives FDA approval for treatment of HIV-1 infection

EMA CHMP recommends conditional marketing authorization of FAMPYRA

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

Complementary and alternative health practices show promise for management of pain

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints

Eli Lilly responds to Amylin's exenatide lawsuit

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

FDA nod for hepatitis C drug

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in